Sarah Sanchez

Sarah Sanchez

Auto-generated profile, based on publicly available information

Sarah Sanchez

Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
TDTanushree Dangi
Tanushree Dangi
NPNicole Palacio
Nicole Palacio
SSSarah Sanchez
Sarah Sanchez
MPMincheol Park
Mincheol Park
JCJacob Class
Jacob Class
PPPablo Penaloza-MacMaster
Pablo Penaloza-MacMaster
Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have shown efficacy against SARS-CoV-2, it is unknown if coronavirus vaccines can also protect against other coronaviruses that may infect humans in the future. Here, we show that coronavirus vaccines elicited cross-protective immune responses against heterologous coronaviruses. In particular, we show that a severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) vaccine developed in 2004 and known to protect against SARS-CoV-1 conferred robust heterologous protection against SARS-CoV-2 in mice. Similarly, prior coronavirus infections conferred heterologous protection against distinct coronaviruses. Cross-reactive immunity was also reported in patients with coronavirus disease 2019 (COVID-19) and in individuals who received SARS-CoV-2 vaccines, and transfer of plasma from these individuals into mice improved protection against coronavirus challenges. These findings provide the first demonstration to our knowledge that coronavirus vaccines (and prior coronavirus infections) can confer broad protection against heterologous coronaviruses and establish a rationale for universal coronavirus vaccines.

1 December 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
TDTanushree Dangi
Tanushree Dangi
SSSarah Sanchez
Sarah Sanchez
JCJacob Class
Jacob Class
MRMichelle Richner
Michelle Richner
LVLavanya Visvabharathy
Lavanya Visvabharathy
PPPablo Penaloza-MacMaster
Pablo Penaloza-MacMaster
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the main antigen in all approved COVID-19 vaccines and is also the only target for monoclonal antibody (mAb) therapies. Immune responses to other viral antigens are generated after SARS-CoV-2 infection, but their contribution to the antiviral response remains unclear. Here, we interrogated whether nucleocapsid-specific antibodies can improve protection against SARS-CoV-2. We first immunized mice with a nucleocapsid-based vaccine and then transferred sera from these mice into naive mice, followed by challenge with SARS-CoV-2. We show that mice that received nucleocapsid-specific sera or a nucleocapsid-specific mAb exhibited enhanced control of SARS-CoV-2. Nucleocapsid-specific antibodies elicited NK-mediated, antibody-dependent cellular cytotoxicity (ADCC) against infected cells. To our knowledge, these findings provide the first demonstration in the coronavirus literature that antibody responses specific to the nucleocapsid protein can improve viral clearance, providing a rationale for the clinical evaluation of nucleocapsid-based mAb therapies to treat COVID-19.

3 December 2021 in Science Immunology
Verified
Journal Article
Open access
SSSarah Sanchez
Sarah Sanchez
NPNicole Palacio
Nicole Palacio
TDTanushree Dangi
Tanushree Dangi
TCThomas Ciucci
Thomas Ciucci
PPPablo Penaloza-MacMaster
Pablo Penaloza-MacMaster
Reducing the priming dose of an SARS-CoV-2 Ad5-based vaccine improves cellular and humoral responses against SARS-CoV-2.

10 November 2025 in JCI Insight
Verified
Journal Article
Open access
BABakare Awakoaiye
Bakare Awakoaiye
SLShiyi Li
Shiyi Li
SSSarah Sanchez
Sarah Sanchez
TDTanushree Dangi
Tanushree Dangi
NINahid Irani
Nahid Irani
PPPablo Penaloza-MacMaster
Pablo Penaloza-MacMaster
Despite the widespread use of adenovirus, mRNA, and protein-based vaccines during the COVID-19 pandemic, their relative immunological profiles and protective efficacies remain incompletely defined. Here, we compared antigen kinetics, innate and adaptive immune responses, and protective efficacy following Ad5, mRNA, and protein vaccination in mice. Ad5 induced the most sustained antigen expression, but mRNA induced the most potent IFN responses, associated with robust antigen presentation and costimulation. Unlike Ad5 vaccines, which were hindered by preexisting vector immunity, mRNA vaccines retained efficacy after repeated use. As a single-dose regimen, Ad5 vaccines elicited higher immune responses. However, as a prime-boost regimen, and particularly in Ad5 seropositive mice, mRNA vaccines were more immunogenic than the other vaccine platforms. These findings highlight strengths of each vaccine platform and underscore the importance of host serostatus in determining optimal vaccine performance.

21 October 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SSSarah Sanchez
Sarah Sanchez
TDTanushree Dangi
Tanushree Dangi
BABakare Awakoaiye
Bakare Awakoaiye
MLMin Han Lew
Min Han Lew
NINahid Irani
Nahid Irani
PPPablo Penaloza-MacMaster
Pablo Penaloza-MacMaster
MRNA vaccines have demonstrated efficacy during the COVID-19 pandemic and are now being investigated for multiple diseases. However, concerns linger about the durability of immune responses, and the high incidence of breakthrough infections among vaccinated individuals highlights the need for improved mRNA vaccines. In this study, we investigated the effects of reinforcing costimulation via 4-1BB, a member of the TNF receptor superfamily, on immune responses elicited by mRNA vaccines. We first immunized mice with mRNA vaccines, followed by treatment with 4-1BB costimulatory antibodies to reinforce the 4-1BB pathway at different time points after vaccination. Consistent with prior studies, reinforcing 4-1BB costimulation on the day of vaccination did not result in a substantial improvement in vaccine responses. However, reinforcing 4-1BB costimulation on day 4 after vaccination, when 4-1BB expression levels were highest, resulted in a profound improvement in CD8 + T cell responses associated with enhanced protection against pathogen challenges. A similar clinical benefit was observed in a therapeutic cancer vaccine model. We also report time-dependent effects with OX40, another costimulatory molecule of the TNF receptor superfamily. These findings demonstrate that delayed reinforcement of costimulation may exert an immunologic benefit, providing insights for the development of more effective mRNA vaccines for infectious diseases and cancer.